What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Gene
- Heart failure
His primary areas of study are Internal medicine, Heart failure, Cardiology, Endocrinology and Ejection fraction.
Renin–angiotensin system, Proportional hazards model, Biomarker, Natriuretic peptide and Idiopathic dilated cardiomyopathy are the primary areas of interest in his Internal medicine study.
The study incorporates disciplines such as Fibrosis, Myocardial infarction and Intensive care medicine in addition to Heart failure.
He has included themes like Gastroenterology and Infarction in his Endocrinology study.
Rudolf A. de Boer combines subjects such as Cohort study, Renal function, Left bundle branch block, Hazard ratio and Heart disease with his study of Ejection fraction.
His research integrates issues of Galectin-3 and Immunology in his study of Ventricular remodeling.
His most cited work include:
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction (1150 citations)
- Identification of seven loci affecting mean telomere length and their association with disease (578 citations)
- Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction (411 citations)
What are the main themes of his work throughout his whole career to date?
Rudolf A. de Boer mainly focuses on Internal medicine, Heart failure, Cardiology, Endocrinology and Ejection fraction.
All of his Internal medicine and Myocardial infarction, Fibrosis, Hazard ratio, Renal function and Cardiomyopathy investigations are sub-components of the entire Internal medicine study.
His Heart failure research is multidisciplinary, incorporating elements of Biomarker, Galectin-3, Disease and Intensive care medicine.
His studies in Disease integrate themes in fields like Cancer, Genetics and Bioinformatics.
His Heart failure with preserved ejection fraction, Dilated cardiomyopathy, Atrial fibrillation and Cardiac function curve study in the realm of Cardiology connects with subjects such as In patient.
His Ejection fraction research incorporates themes from Diabetes mellitus and Dapagliflozin.
He most often published in these fields:
- Internal medicine (72.93%)
- Heart failure (56.36%)
- Cardiology (43.84%)
What were the highlights of his more recent work (between 2019-2021)?
- Internal medicine (72.93%)
- Heart failure (56.36%)
- Cardiology (43.84%)
In recent papers he was focusing on the following fields of study:
Rudolf A. de Boer mostly deals with Internal medicine, Heart failure, Cardiology, Ejection fraction and Disease.
His studies link Dapagliflozin with Internal medicine.
His research in Heart failure intersects with topics in Body mass index, Bioinformatics, Cardiotoxicity, Myocardial infarction and Biomarker.
Cardiology is frequently linked to Fibrosis in his study.
His Disease research includes themes of Cancer and Dilated cardiomyopathy.
His Atrial fibrillation research is multidisciplinary, incorporating perspectives in Coronary artery disease and Cohort study.
Between 2019 and 2021, his most popular works were:
- Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes (76 citations)
- Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society (50 citations)
- European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure. (44 citations)
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
